Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Semax (SEM) is a cognitive peptide, at the approved in russia stage in the published literature. Synthetic peptide derived from ACTH with powerful nootropic and neuroprotective effects. Developed in Russia and approved for stroke and cognitive disorders.
Synthetic peptide derived from ACTH with powerful nootropic and neuroprotective effects. Developed in Russia and approved for stroke and cognitive disorders.
| Research Status | Approved in Russia |
|---|---|
| Half-Life | Minutes (rapid absorption) |
| Administration | Intranasal |
| Doses Reported in Published Studies | 200-600 mcg |
Increases BDNF expression, modulates dopamine and serotonin systems, enhances neuroplasticity and NGF.
Synthetic peptide derived from ACTH with powerful nootropic and neuroprotective effects. Developed in Russia and approved for stroke and cognitive disorders.
Increases BDNF expression, modulates dopamine and serotonin systems, enhances neuroplasticity and NGF.
Semax is at the following stage in the published literature: Approved in Russia. All information is for research and educational purposes only.
Reported half-life: Minutes (rapid absorption).
Reported administration route in the literature: Intranasal. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.